0000002468 00000 n Sprache : Französisch Pdf - 955 KB - 221 Seite(n) Herunterladen In anderen Sprachen. 0000008041 00000 n Listes de prix des médicaments This policy applies to drugs … liste des médicaments admis. Liste des médicaments commercialisés valable au 1er octobre 2020 Cette liste se base sur des données qui sont de la compétence de la Direction de la Santé, Division de la Pharmacie et des Médicaments, du Ministère de la sécurité sociale et de la Caisse nationale de santé. 0000006926 00000 n 0000011265 00000 n endstream endobj 24570 0 obj<>/Size 24551/Type/XRef>>stream Les questions à la conférencière peuvent être … Liste des spécialités LS. ANESTHESIQUES 1.1 Anesthésiques généraux et oxygène halothane Inhalation. Short description: The eEML is a comprehensive, freely accessible, online database containing … (Voir Liste indicative des produits hospitaliers Annexe 3) 1.2 Combien faut-il commander de médicaments ? 17e édition (Révision) Médicaments essentiels Liste modèle de lʹOMS (mars 2011) Note explicatives La liste principale correspond aux besoins minimaux en médicaments d’un système de soins de santé de base et indique les médicaments qui ont la meilleure efficacité, la meilleure innocuité et le meilleur rapport Toutes les informations accessibles sont mises à jour régulièrement et proviennent directement de sources fiables : ANSM (Agence Nationale de … Section 4 : Médicaments et formulaire Le français suivra. Cette liste de médicaments doit être établie en tenant compte de la personne âgée. The WHO Model Lists of Essential Medicines has been updated every two years since 1977. startxref Liste des spécialités Ordre … Liste der Antigentests gem. Mit Flexionstabellen der verschiedenen Fälle und Zeiten Aussprache und relevante Diskussionen Kostenloser Vokabeltrainer 0 Liste des médicaments contre-indiqués Les anti-arythmiques Classe 1: Ajmaline Cibenzoline Dihydroquinidine Disopyramide Encainide Flecainide Mexiletine Pirmenol Procainamide Propafenone Quinidine Classe 3: Almokalant Amiodarone Azimilide Bretylium Dofetilide NB Drug Plans Prescriber List/Liste des prescripteurs des régimes médicaments du N.-B. Forumsdiskussionen, die den Suchbegriff enthalten; liste rouge - vor allem Liste der … 91/2020 DIN Product Name Manufacturer Price ($) Prix ($) Price ($) + 5% Prix ($) + 5 % NIM Produit Fabricant ACYCLOVIR — 200 mg — Tablets Per Par Per Par ACYCLOVIR — 200 mg — comprimés Tablet comprimé Tablet comprimé 02285959 Novo-Acyclovir TEV 0.8783 … Flyer Télécharger PDF; Comment les nouveaux médicaments sont-ils développés ? kétamine Solution injectable: 50 mg (sous forme de chlorhydrate)/ml, en flacon de 10 ml. Contenu de la liste La LNME version 2010 comprend trois parties : • 1ère partie : les médicaments … �L%�LF��dDS�n-�@���"�‚!�UBBIɘp�����C�/;A�bM��5x�'��0p7�;'1�t١���Б% {D7�`c�e�p��ю����A��B! Comment puis-je participer à une étude clinique ? 0000009253 00000 n Lorsque la présente liste limite la prescription de médicaments par la mention L, le médecin doit respecter cette limitation. Art der Veröffentlichung Dekret Erscheinungsdatum 01/01/2021. 0000006090 00000 n 0000004023 00000 n 91/2020 R.M. : annexe décret : contrat type, mais contrat individualisé par établissement avec engagements spécifiques sur certains produits (cancérologie, MDS, DMI, …) ARH fixe chaque année sur la base du rapport annuel le taux de prise en charge des produits remboursés hors T2A (de 70 … Liste Nationale des Médicaments Essentiels Avantages de la LNME ix propriétés plus favorables, qui résiste le mieux à l’épreuve du stockage et facile à se procurer et qui est plus actif. Liste des Médicaments D délivrés en ambulatoire La liste des médicaments non remboursables par l'INAMI pris en charge par les CPAS de la Région de Bruxelles est établie en suivant ce cadre général dressé par la Commission des Médicaments. Médicaments génériques : des médicaments à part entière - Rapport de l’ANSM (14/12/2012) (1430 ko) Pour toute question, écrire à repertoiregeneriques@ansm.sante.fr Liste des médicaments génériques Last execution date: 13/01/2021 32 SOLIDAGO Prestat. 0000002962 00000 n Liste des médicaments avec tarif Edition du 1° avril 2020 . PDF Excel (XLSX) Word (DOCX) You can select particular sections to be included in the output file. 0000010501 00000 n Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL, Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate), Parenteral > General injections > IV: 3750 units per 5 mL in vial, Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe, Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe, Parenteral > General injections > IM: 200 mg (as isetionate) powder for injection, Oral > Solid: 200 mg tablet; 300 mg tablet, Parenteral > General injections > IV: 200 mg per mL in ampoule (phenobarbital sodium), Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid, Oral > Solid: 250 mg (as potassium salt) tablet, Oral > Solid: 25 mg (sodium salt); 100 mg (sodium salt); 50 mg (sodium salt); 50 mg chewable tablet, Parenteral > General injections > unspecified: 50 mg per mL in 5 vial (sodium salt), Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule, Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate), Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection, Parenteral > General injections > IV: 500 mg per 10 mL (Injection), Parenteral > General injections > IV: 3.5% injectable solution, Parenteral > General injections > unspecified: 500000 IU in vial powder for injection, Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL), Oral > Solid: Powder for oral administration, Local > Topical > Solution: Saturated solution, Local > Topical > Solution: aqueous solution: 1:10 000, Local > Topical > Solution: 10% (equivalent to 1% available iodine), Oral > Solid: 600 mg tablet; 150 mg tablet, Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate), Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate), Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection, Local > Vaginal > vaginal ring: 2.074 g micronized progesterone, Oral > Solid: 100 mg tablet (hydrochloride), Parenteral > General injections > unspecified: 10 mg per mL; 20 mg per mL, Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride), Parenteral > General injections > IV: 0.5 mg per mL in alcohol, Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule, Oral > Liquid: 50 mg per mL (as embonate or pamoate), Oral > Solid: 250 mg chewable tablet (as embonate or pamoate), Oral > Solid: 400 mg tablet; 150 mg tablet (dispersible); 150 mg tablet (scored), Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide), Oral > Solid: 60 mg (pyridostigmine bromide), Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride), Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate), Oral > Solid: 400 mg tablet; 25 mg tablet (chewable); 100 mg tablet (chewable), Oral > Other: 100 mg granules for oral suspension, Oral > Liquid: 75 mg per 5 mL (as hydrochloride), Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride), Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg), Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection, Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser, Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule, Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution, Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg, Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable), Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial, Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate), Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler, Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers, Local > Topical > Suspension: 2% detergent-based, Oral > Liquid: 7.5 mg per 5 mL oral liquid, Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms), Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule, Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L), Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L), Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule, Parenteral > General injections > IV: 50 mg in ampoule powder for infusion, Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial, Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule, Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection, Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL, Parenteral > General injections > IV: 1.5 million IU in vial powder for injection, Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial, Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule, Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid, Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet, Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule, Parenteral > General injections > IV: 1 g in vial, Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation, Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial, Oral > Solid: 10 mg (as citrate); 20 mg (as citrate), Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg, Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg, Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil), Local > Topical > Cream: 1% terbinafine hydrochloride, Local > Topical > Ointment: 1% terbinafine hydrochloride, Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate), Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride), Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride), Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate), Respiratory > Inhalation > dry powder: 18 µg capsule, Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation, Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection, Local > Ophthalmological > Solution (eye drops): 0.5%. � ���s��hmr��n)O��5Ewκƫ�u�{����X���W�̉�f�S��~M��x��2�D�D�����S;��+N%.nsT߱�j�1�9J�]׬n�)�mmU6�:�� f�n'����z�l_X곞�r��\�t�4ܾ�{��@�{?�ݽk��vｋ @���o�޽{�_21�L� r9MYC�]�}T�0���84�@DDE.z ���:��"��)P�as,@��q��G�%�-u�5@(�ʝ"���1Ѕ�!-@��fWE 7��@�lj.3�Qd�MLD��@���0��Ec���9���@n�Fta16��D��^�.\@j4� Dans leur charte, les professionnels du Réseau PIC s’engagent à répondre professionnellement à toutes les personnes souhaitant les interroger par courrier électronique … Bestimmungen über die Leistungspflicht und den Umfang der Vergütung bei Mitteln und Gegenständen, die der Untersuchung oder Behandlung dienen; Intrauterine system with reservoir containing 52 mg of levonorgestrel. 0000011495 00000 n 24551 21 Coronavirus SARS-CoV-2. Liste modèle des médicaments essentiels Section Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Indications Human immunodeficiency virus disease without <<15036CEBAB818E4EA3484B0902355845>]>> non fonction.art.20§3(901) phytotherapie N 3FLUART Frais vaccination grippe saisonnière(526) REMBOURSABLE SUR PRESCRIPTIY 3M CAVILON Produits non remboursables(900) NON REMBOURSABLE CAR EXCLU N 3M CAVILON … 0000000016 00000 n Consultez le règlement pour l'officine publique (PDF, versi 0000004102 00000 n Parenteral > Locoregional injections > Intradermal: Oral > Solid: 30 mg tablet (ulipristal acetate), Oral > Liquid: 50 mg per mL powder for oral solution, Oral > Liquid: 200 mg per 5 mL (sodium valproate), Oral > Solid: 200 mg (sodium valproate) enteric-coated tablet; 500 mg (sodium valproate) enteric-coated tablet; 100 mg (sodium valproate) crushable tablet, Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule (sodium valproate); 100 mg per mL in 10 mL ampoule (sodium valproate), Oral > Solid: 200 mg enteric-coated (sodium valproate); 500 mg enteric-coated (sodium valproate), Oral > Solid: 125 mg (as hydrochloride); 250 mg (as hydrochloride), Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection, Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide), Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride), Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride), Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate), Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate), Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial, Parenteral > General injections > IV: 200 mg in vial powder for injection, Oral > Liquid: 40 mg per mL powder for oral liquid, Oral > Solid: 50 mg tablet; 200 mg tablet, Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt), Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule, Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL, Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection, Oral > Solid: 250 mg capsule; 300 mg tablet, Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle. En outre, la pathologie iatrogène est beaucoup plus grave chez le sujet âgé. Removed medicines and rejected applications are not shown. Spécialités et Génériques : Informationen zum ... PDF | 201KB 23.12.2020Rote-Hand-Brief zu Oncofolic® 50 mg/ml Injektions- oder Infusionslösung: … Die Firma Medac Gesellschaft für klinische Spezialpräparate mbH informiert darüber, dass während der Konfektionierung von Oncofolic® 50 mg/ml … Priority conditions are … Paper copies are not maintained. But de la liste de médicaments du Programme des SSNA La liste des médicaments contient les médicaments couverts par le Programme des SSNA. 24551 0 obj <> endobj Médicaments essentiels 15e édition (mars 2007) Liste modèle de lʹOMS LME 15 page - 1 1. Drug Price Lists Listes de prix des médicaments Page 1 The electronic version of this policy is the official version. Des copies papier ne sont pas conservées. ATTENTION : il s'agit de recommandations thérapeutiques concernant les produits en vente en pharmacie. Found 1098 recommendations for 557 medicines and 44 therapeutic equivalents, Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified, Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteriodal anti-inflammatory drugs, Acute rheumatic fever without mention of heart involvement, Unspecified injury, poisoning or certain other consequences of external causes, Other specified malignant neoplasms of bronchus or lung, Acute myeloid leukaemia with recurrent genetic abnormalities, Inflammatory and other diseases of prostate (severe), Multi-drug resistant tuberculous Mycobacterium, Amodiaquine + sulfadoxine + pyrimethamine, Acute malnutrition in infants, children or adolescents (uncomplicated) [children], Acute malnutrition in infants, children or adolescents (complicated) [children], Bacterial pneumonia (Community-acquired pneumonia - mild to moderate), Chronic obstructive pulmonary disease with acute exacerbation, Bacterial pneumonia (Community-acquired pneumonia - severe) [children], Other specified pneumonia (Hospital-acquired pneumonia), Bacterial cellulitis, erysipelas and lymphangitis, Bacterial pneumonia (Community-acquired pneumonia - severe), Other specified malignant neoplasms of breast, Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified, Skeletal muscle relaxants [neuromuscular blocking agents], Exposure to or harmful effects of undetermined intent of pesticides, Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, Failure or rejection of transplanted organs or tissues, Gastroenteritis and colitis without specification of infectious agent, Need for immunization against tuberculosis, Chronic lymphocytic leukaemia or small lymphocytic lymphoma, Other specified malignant neoplasms of the ovary, Kaposi sarcoma of unspecified primary site, Malignant neoplasm metastasis in large intestine, Malignant trophoblastic neoplasms of placenta, Burkitt lymphoma including Burkitt leukaemia, Osteosarcoma of bone and articular cartilage of unspecified sites, Inflammatory and other diseases of prostate (mild to moderate), Pseudomonas aeruginosa resistant to other antibiotic, Carbapenem resistant Acinetobacter baumannii, Carbapenem-resistant Pseudomonas aeruginosa, Schizophrenia or other primary psychotic disorders, Need for immunization against cholera alone, Helicobacter pylori associated gastric ulcer, Female infertility without specification whether primary or secondary, Presence of coronary angioplasty implant or graft, Coagulation defects, purpura or other haemorrhagic or related conditions, Other specified disorders of fluid, electrolyte or acid-base balance, Contact with health services for contraceptive management, Contact with health services for insertion of contraceptive device, Ewing sarcoma of bone and articular cartilage of unspecified sites, Malignant neoplasms of kidney, except renal pelvis, Harmful effects of drugs, medicaments or biological substances, not elsewhere classified, Other specified sickle cell disorders or other haemoglobinopathies, Need for immunization against certain single viral diseases, Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy, Allergic or hypersensitivity conditions of unspecified type, Persistent hyperinsulinemic hypoglycaemia of infancy, Dihydroartemisinin + piperaquine phosphate, Need for immunization against diphtheria alone, Contact with or exposure to human immunodeficiency virus, Estradiol cypionate + medroxyprogesterone acetate, Contact with health services for reasons associated with reproduction, Ethambutol + isoniazid + pyrazinamide + rifampicin, Nutritional anaemias complicating pregnancy, childbirth and the puerperium, Blood transfusion without reported diagnosis, Hypoglycaemia without associated diabetes, Need for immunization against single bacterial diseases, Need for immunization against viral hepatitis, Megaloblastic anaemia due to vitamin B12 deficiency, Gastrointestinal stromal tumour of unspecified gastrointestinal sites, Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim, Contact with health services for postcoital contraception, Methicillin resistant Staphylococcus aureus, Vancomycin resistant Staphylococcus aureus, Need for immunization against measles alone, Excessive menstruation with irregular cycle, Osteosarcoma of bone and articular cartilage of other specified sites, Enterocolitis due to Clostridium difficile, Termination of pregnancy, affecting surviving fetus or newborn, Unspecified abortion, incomplete, without complication, Need for immunization against mumps alone, Unintentional exposure to or harmful effects of opioids or related analgesics, Influenza due to seasonal identified influenza virus, Schistosomiasis due to Schistosoma mansoni, Need for immunization against pertussis alone, Haemorrhagic disorder due to other specified circulating anticoagulants, Haemorrhagic or haematological disorders of foetus or newborn, Need for immunization against poliomyelitis, Other specified pyogenic bacterial infection of skin and subcutaneous tissue, Other specified congenital anomaly of great arteries including arterial duct, Viral haemorrhagic fever, not elsewhere classified, Need for immunization against rubella alone, Testicular dysfunction or testosterone-related disorders, Need for immunization against tetanus alone, Neonatal conjunctivitis or dacryocystitis, Need for immunization against arthropod-borne viral encephalitis, Need for immunization against typhoid-paratyphoid alone, Kaposi sarcoma of other specified primary sites, Other specified diseases of arteries or arterioles, Cerebral ischaemic stroke due to embolic occlusion, Unspecified appropriateness of dosing or administration without injury or harm, Malignant neoplasm metastasis in bone or bone marrow, Oral > Solid: 60 mg tablet (dispersible, scored) (as sulfate); 300 mg tablet (as sulfate), Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored), Local > Otological > drops: 2% in alcohol, Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule, Local > Rectal > Suppository: 50 to 150 mg, Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt), Local > Ophthalmological > Ointment: 3% w/w, Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL, Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol, Oral > Solid: 100 mg tablet; 300 mg tablet, Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection, Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt), Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate), Parenteral > General injections > unspecified: 1 g in vial powder for injection (as sulfate); 500 mg in vial powder for injection (as sulfate); 100 mg in vial powder for injection (as sulfate), Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride), Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride), Oral > Solid: 5 mg (as maleate, mesylate or besylate), Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride), Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package, Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid, Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate), Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection, Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection, Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid, Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt), Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex), Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection, Parenteral > General injections > IV: 250 µg in single-dose vial, Parenteral > General injections > IM: 250 µg in single-dose vial, Parenteral > General injections > IM: 150 IU per mL in vial, Parenteral > Locoregional injections > Other: 150 IU per mL in vial, Parenteral > General injections > IM: 500 IU in vial, Oral > Liquid: 125 mg powder for oral suspension (in sachet), Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion, Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection), Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet, Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution, Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules, Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet, Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet, Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules, Parenteral > General injections > unspecified: 10000 IU in vial powder for injection, Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate), Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable), Parenteral > General injections > IV: 10 mg per mL (besylate), Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate), Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate), Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt), Local > Ophthalmological > Solution (eye drops): 1.5% eye drops, Oral > Liquid: 200 mg per 5 mL oral liquid, Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule. Annex 1 19th WHO Model List of Essential Medicines (April 2015) Explanatory notes The core list presents a list of minimum medicine needs for a basic health‐care system, listing the most efficacious, safe and cost–effective medicines for priority conditions. 0000003759 00000 n CONTEXTE DE L’ETUDE ET … Quelles sont les différentes phases d’un essai clinique ? 0000005185 00000 n M.R. 2011 . La version électronique de cette politique est la version officielle. Actuellement, plusieurs pays disposent d’une Liste Nationale de Médicaments Essentiels (LNME). Powder for dilution in 200 mL, 500 mL, 1 L: Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged), Oral > Liquid: 12 mg per mL powder for oral liquid, Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate), Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial, Parenteral > General injections > unspecified: 10 IU per mL, Oral > Solid: 500 mg tablet; 4 g granules in sachet, Parenteral > General injections > IV: 6 mg per mL. 17e édition (Révision) Médicaments essentiels Liste modèle de lʹOMS (mars 2011) Note explicatives La liste principale correspond aux besoins minimaux en médicaments d'un système de soins de santé de base et indique les médicaments qui ont la meilleure efficacité, la meilleure innocuité et le meilleur rappor L'Organisation … Implant > Subdermal: 75 mg per rod (two-rods), Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt), Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride), Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution, Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride), Local > Topical > unspecified: 2 to 4% (hydrochloride), Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial, Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine, Parenteral > General injections > IV: 2 mg per mL in 300 mL bag, Oral > Solid: 400 mg tablet; 600 mg tablet; 150 mg tablet (dispersible), Oral > Solid: 400 mg tablet; 600 mg tablet, Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg, Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg, Oral > Solid: 2 mg solid oral dosage form, Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg, Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule, Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet, Oral > Liquid: 13% w/v (about 130 mg/mL total iodine), Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume), Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume), Parenteral > General injections > IV: 10% solution; 20% solution, Oral > Solid: 100 mg tablet (chewable); 500 mg tablet (chewable), Parenteral > General injections > IM: 150 mg per mL in 1 mL vial, Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system, Oral > Solid: 250 mg tablet (hydrochloride), Parenteral > General injections > IM: 30% in 5 mL ampoule equivalent to approximately 8.1% antimony, Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL, Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound), Parenteral > General injections > IV: 50 mg in vial powder for injection, Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection, Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection, Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule, Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride), Oral > Liquid: 5 mg per 5 mL (as hydrochloride); 10 mg per 5 mL (as hydrochloride); 5 mg per mL concentrate for oral liquid (as hydrochloride); 10 mg per mL concentrate for oral liquid (as hydrochloride), Oral > Solid: 5 mg (as hydrochloride); 10 mg (as hydrochloride), Parenteral > General injections > IV: 50 mg in vial (as sodium salt), Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate), Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule, Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride), Oral > Liquid: 200 mg per 5 mL (as benzoate), Local > Rectal > Suppository: 500 mg suppository; 1 g suppository, Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection, Parenteral > General injections > unspecified: 500 mg in 100 mL vial, Parenteral > General injections > IV: 1 mg per mL, Oral > Solid: 15 mg tablet; 7.5 mg tablet, Parenteral > General injections > unspecified: 1 mg per mL in ampoule (for buccal administration); 10 mg per mL in ampoule (for buccal administration), Local > Buccal > Solution: 5 mg per mL solution for oromucosal administration; 10 mg per mL solution for oromucosal administration, Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form, Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection, Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package, Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate), Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate), Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate), Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate), Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride), Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible), Local > Topical > Cream: 2% (as mupirocin calcium), Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride), Local > Ophthalmological > Suspension: 5% eye drops, Oral > Solid: 15 mg (neostigmine bromide), Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate), Oral > Liquid: 50 mg per 5 mL oral solution, Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible), Oral > Other: 2 mg chewing gum; 4 mg chewing gum, Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour, Oral > Solid: 30 mg tablet; 120 mg tablet; 250 mg tablet, Oral > Solid: 150 mg capsule; 200 mg capsule, Oral > Liquid: 25 mg per 5 mL oral liquid, Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion, Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution, Parenteral > General injections > IV: 5% protein solution; 10% protein solution, Parenteral > General injections > IM: 16% protein solution, Parenteral > General injections > SC: 15% protein solution; 16% protein solution, Oral > Liquid: 100000 IU per mL; 50 mg per 5 mL, Oral > Solid: 500000 IU tablet; 100000 IU lozenge; 100000 IU tablet, Local > Topical > Other: 100000 IU pessary, Local > Ophthalmological > Solution (eye drops): 0.3%, Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet, Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid, Parenteral > General injections > IV: 40 mg in vial, Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride), Oral > Liquid: 4 mg per 5 mL (ondansetron base), Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base), Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base).

Pronostic Real Sociedad Athletic Bilbao, Accepter De Ne Pas être Aimé, Inspecteur Du Travail, Allemagne Foot Match, 26 Juin 1997, Horaire Train Tunis, Installer Mytf1 Sur Pc, Dessin Crayon Papier Paysage, Mon âne Paroles,